Swiss researchers have identified a vicious cycle of protein aggregation that starves neurons of energy and fuels amyloid buildup. An experimental compound breaks the loop—and hints at broader effects on aging.
Why this matters
Alzheimer’s disease has resisted every attempt at a cure. Existing drugs delay progression by months at best, and the amyloid hypothesis—though dominant for decades—has produced more failures than breakthroughs. The problem may be that we’ve been aiming at the wrong target.
A team at ETH Zurich, led by molecular pharmacologist Ursula Quitterer, has spent nearly two decades tracing a different culprit: an enzyme called GRK2. When this protein gets inactivated by cellular metabolism, it doesn’t just stop working—it clumps together and physically blocks the pores of mitochondria, the organelles that supply neurons with ATP. The result is an energy crisis inside the cell, a state of chronic stress that triggers amyloid beta production and, ultimately, neuronal death.
This is a fundamentally different mechanism from the one targeted by current drugs. It’s not about clearing plaques—it’s about preventing the cellular power failure that drives the disease in the first place. And because the same mitochondrial dysfunction appears in heart failure and aging, the implications may extend far beyond dementia.
What was found
Quitterer’s team analyzed brain tissue from dementia patients and non-demented controls, obtained from a colleague at Ain Shams University Hospital in Cairo. They found unusually high levels of the inactive form of GRK2 in the dementia brains. In a mouse model of Alzheimer’s, they observed the same pattern—and watched as these inactive GRK2 molecules aggregated on mitochondrial membranes.
The aggregates physically occlude the mitochondrial pores, reducing energy output and increasing cellular stress. That stress, in turn, promotes more GRK2 inactivation and aggregation, creating a self-amplifying loop. The team also showed that inactive GRK2 increases amyloid beta production, which adds further stress—a vicious circle that accelerates neurodegeneration.
To break this cycle, the researchers designed a series of compounds and tested them in cell cultures and mice. Compound 10 stood out: it prevented GRK2 aggregation, restored mitochondrial function, reduced amyloid accumulation, and protected neurons from death. Treated mice lived longer, and—unexpectedly—showed improved heart function and fewer grey hairs, suggesting a broader impact on aging processes.
How to interpret it
This is a preclinical study, and the results are in mice, not humans. The mouse model of Alzheimer’s recapitulates some but not all features of the human disease, and the compound has not been tested for safety or efficacy in people. The findings are promising, but they are not proof that Compound 10 will work in humans.
The broader effects on heart and aging are intriguing but preliminary. They suggest that GRK2 aggregation may be a shared mechanism across age-related diseases, but this is speculation at this point. The researchers themselves emphasize that Alzheimer’s is complex and that this is one piece of the puzzle.
What is solid is the mechanistic insight: GRK2 aggregation disrupts mitochondrial function, and preventing that aggregation has beneficial effects in an animal model. This opens a new avenue for drug development, one that could complement existing therapies rather than replace them.
Practical next steps
For now, there is no actionable clinical advice. Compound 10 is not a drug; it’s a research tool. The team has applied for a patent and is seeking industry partners to move it toward human trials, but that process will take years.
In the meantime, the findings reinforce the importance of mitochondrial health in neurodegeneration. Lifestyle factors that support mitochondrial function—regular exercise, adequate sleep, stress management—remain the most evidence-based strategies for reducing dementia risk. These interventions are not a cure, but they are within your control.
The deeper lesson from this research is that aging itself is a risk factor for Alzheimer’s, and that the disease may be driven by fundamental cellular processes that go awry with time. Understanding those processes—and finding ways to keep them running smoothly—is the frontier of longevity science.
Three things to remember
- GRK2 aggregates block mitochondrial pores, starving neurons of energy.
- Compound 10 prevents GRK2 aggregation, reducing amyloid and neuronal death.
- Preclinical only; human trials are years away.
Source
This analysis is based on A little-known protein may be fueling Alzheimer’s — and scientists found a way to block it from ScienceDaily Healthy Aging. Read the original report for full context.
Health note: This is a preclinical study in mice. Compound 10 has not been tested in humans and is not a treatment for Alzheimer’s disease.